Ardelyx to Present at the 2015 Wedbush PacGrow Healthcare Conference

Aug 05, 2015, 08:00 ET from Ardelyx

FREMONT, Calif., Aug. 5, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mike Raab, Chief Executive Officer, will present an overview of the company at the Wedbush PacGrow Healthcare Conference at 12:45 p.m. Eastern Time on August 12, 2015 at Le Parker Meridien in New York City.

The presentation will be available through a live audio webcast accessible through a link in the Investor Relations section of the Ardelyx website at A replay of the webcast will be available for 14 days at the site after the presentation.

About Ardelyx

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, the Company has discovered and designed tenapanor, which it is evaluating for the treatment of IBS-C and hyperphosphatemia in chronic kidney disease patients on dialysis. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients, and has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in CKD patients on dialysis, a program licensed to Sanofi.  Ardelyx is also independently advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at

Logo -


SOURCE Ardelyx